Differential mRNA expression of urokinase-type plasminogen activator, plasminogen activator receptor and plasminogen activator inhibitor type-2 in normal human endometria and endometrial carcinomas

Gynecologic Oncology

Volumn 79, Issue 2, 2000, Pages 244-250

  Foca, C ^a,b   Moses, E K ^a,b   Quinn, M A ^b   Rice, G E ^a,b  

^a ROYAL WOMEN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Endometrial neoplasms; Gene expression; Plasminogen activator; Plasminogen activator inhibitor 2; Urokinase receptor

Indexed keywords

PLASMINOGEN ACTIVATOR; PLASMINOGEN ACTIVATOR INHIBITOR 2; RNA 18S; UROKINASE; UROKINASE RECEPTOR;

ARTICLE; CANCER GROWTH; CANCER INVASION; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOMETRIUM CARCINOMA; FEMALE; GENE EXPRESSION; GENETIC CODE; HUMAN; HUMAN TISSUE; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; RECEPTOR UPREGULATION;

EID: 0033756855     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.2000.5959     Document Type: Article

References (26)

1. Expression of urokinase type plasminogen activator and its receptor during ovarian follicular development
2. Presence of urokinase plasminogen activator and plasminogen activator inhibitor-1 messenger ribonucleic acids in rat endometrium during decidualization in vivo
3. Immunohistochemical localization of urokinase-type plasminogen activator and plasminogen activator inhibitors 1 and 2 in early human implantation sites
4. Induction of vascular SMC proliferation by urokinase indicates a novel mechanism of action in vasoproliferative disorders
5. Urokinase-dependent angiogenesis in vitro and diacylglycerol production are blocked by antisense oligonucleotides against the urokinase receptor
6. Direct stimulation of urokinase, plasmin and collagenase by meperidine: A possible mechanism for the ability of meperidine to enhance cervical effacement and dilation
7. Receptor mediated endocytosis of plasminogen activators and activator/inhibitor complexes
8. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients
9. Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas
10. The plasminogen activator urokinase and its inhibitor PAI-2 in endometrial cancer
11. Isolation of biologically active ribonucelic acid from sources enriched in ribonuclease
12. Plasminogen activators, their inhibitors and urokinase receptor emerge in late stages of melanocytic tumor progression
13. Localisation of urokinase-type plasminogen activator in stromal cells in adenocarcinomas of the colon in humans
14. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas
15. Tumor associated proteolytic factors uPA and PAI-1 in endometrial carcinoma
16. Discordant expression of mRNA and protein for urokinase and tissue plasminogen activators (uPA, tPA) in endometrial carcinoma
17. The urokinase receptor-protein structure and role in plasminogen activation and cancer invasion
18. Modulation of urokinase-type plasminogen activator gene expression by inflammatory cytokines in human pre-B lymphoma cell line RC-K8
19. Oestradiol regulation of the components of the plasminogen-plasmin system in MDA-MDB-231 human breast cancer cells stably expressing the estrogen receptor
20. Invasive capacity and regulation of urokinase-type plasminogen activator in estrogen receptor (ER)-negative MDA-MDB-231 human breast cancer cells, and a transfectant (S30) stably expressing ER
21. Cytokine regulated urokinase type plasminogen activator (uPA) production by human breast fibroblast in vitro
22. Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro
23. Modulation of the plasminogen activation system by inflammatory cytokines in human colon carcinoma cells
24. Transcriptional and post-transcriptional regulation of the receptor for urokinase-type plasminogen activator by cytokines and tumour promoters in the human lung carcinoma cell line A549
25. Co-expression of urokionase, urokinase receptor and PAI-1 is necessary for optimum invasiveness of cultured lung cells
26. Plasminogen activator inhibitor-type-2 inhibits tumour necrosis factor alpha-induced apoptosis. Evidence for an alternate biological function